Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Sends Raptiva “Dear Doctor” Letter To Dermatologists, Nurses

This article was originally published in The Pink Sheet Daily

Executive Summary

Letter addresses new warning in efalizumab labeling on immune-mediated hemolytic anemia. Two cases of hemolytic anemia were observed in clinical trials and two additional cases were observed in postmarketing adverse event monitoring.

You may also be interested in...



PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter

Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.

PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter

Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.

Genentech Will Alert Physicians To Raptiva Anemia Warning

"Dear Healthcare Provider" letter will address a hemolytic anemia warning stemming from postmarketing surveillance of the plaque psoriasis therapy. A precaution on severe arthritis events also has been added.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel